Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells 50,000 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) COO Jonathan Young sold 50,000 shares of the business's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $44.86, for a total transaction of $2,243,000.00. Following the completion of the sale, the chief operating officer now owns 201,147 shares in the company, valued at approximately $9,023,454.42. This trade represents a 19.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Jonathan Young also recently made the following trade(s):

• On Monday, February 3rd, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $53.81, for a total transaction of $538,100.00.
• On Thursday, January 2nd, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $28.03, for a total transaction of $280,300.00.
• On Tuesday, December 10th, Jonathan Young sold 2,503 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.79, for a total transaction of $77,067.37.

Akero Therapeutics Stock Down 3.5 %

AKRO traded down $1.55 on Friday, reaching $42.12. The company's stock had a trading volume of 947,726 shares, compared to its average volume of 844,922. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. Akero Therapeutics, Inc. has a fifty-two week low of $17.86 and a fifty-two week high of $58.40. The stock has a 50 day moving average of $40.49 and a two-hundred day moving average of $33.23. The company has a market capitalization of $2.94 billion, a price-to-earnings ratio of -11.23 and a beta of -0.19.

Remove Ads

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its quarterly earnings data on Friday, February 28th. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.01). As a group, analysts forecast that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Institutional Investors Weigh In On Akero Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. purchased a new stake in shares of Akero Therapeutics during the fourth quarter worth approximately $41,000. Sterling Capital Management LLC raised its stake in shares of Akero Therapeutics by 764.3% during the fourth quarter. Sterling Capital Management LLC now owns 1,789 shares of the company's stock worth $50,000 after purchasing an additional 1,582 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Akero Therapeutics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company's stock worth $71,000 after purchasing an additional 446 shares during the last quarter. Quarry LP purchased a new stake in shares of Akero Therapeutics during the fourth quarter worth approximately $83,000. Finally, Summit Investment Advisors Inc. raised its stake in shares of Akero Therapeutics by 6.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company's stock worth $197,000 after purchasing an additional 450 shares during the last quarter.

Analyst Upgrades and Downgrades

AKRO has been the topic of a number of recent research reports. UBS Group boosted their price target on shares of Akero Therapeutics from $42.00 to $109.00 and gave the stock a "buy" rating in a research note on Friday, January 31st. Citigroup boosted their price objective on Akero Therapeutics from $65.00 to $80.00 and gave the stock a "buy" rating in a research report on Tuesday, January 28th. Morgan Stanley boosted their price objective on Akero Therapeutics from $46.00 to $96.00 and gave the stock an "overweight" rating in a research report on Tuesday, January 28th. Canaccord Genuity Group boosted their price objective on Akero Therapeutics from $56.00 to $73.00 and gave the stock a "buy" rating in a research report on Tuesday, January 28th. Finally, Bank of America raised Akero Therapeutics from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $35.00 to $63.00 in a research report on Thursday, January 30th. Nine analysts have rated the stock with a buy rating, According to MarketBeat, Akero Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $76.29.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.